title: [5 alpha-reductase inhibitors and prostate cancer: a statement of the Committee of Cancerology of the French Association of Urology].
abstract: BACKGROUND
  Two randomised trials and negative conclusion of the FDA about inhibitors of 5 alpha-reductase in prevention of prostate cancer need a revision of the indications of these drugs.
  
  
  METHODS
  After description of fundamentals data, review of the literature in PubMed library was performed to analyse the indications of these drugs according to the different stages of prostate cancer.
  
  
  RESULTS
  Even if PCPT and REDUCE studies showed a decrease of cancers with the use of 5 alpha-reductase (5ARI) but with side effects, there is no indication for prostate cancer prevention by these drugs. In the same way, despite the results of REEDEM study, there is no indication of these drugs in active surveillance.
  
  
  CONCLUSIONS
  Despite the large interest of these drugs, no recommendation can be given for indications of 5ARI in prevention or treatment of prostate cancer.
authors.affiliation: Service d'urologie, CHU de Nancy, avenue de Bourgogne, 54500 Vandœuvre-lès-Nancy, France.
authors.forename: P
authors.initials: P
authors.lastname: Eschwège
authors.forename: N
authors.initials: N
authors.lastname: Gaschignard
authors.forename: G
authors.initials: G
authors.lastname: Ploussard
authors.forename: M
authors.initials: M
authors.lastname: Peyromaure
authors.forename: C
authors.initials: C
authors.lastname: Bastide
authors.forename: L
authors.initials: L
authors.lastname: Cormier
authors.forename: P
authors.initials: P
authors.lastname: Mongiat-Artus
authors.forename: F
authors.initials: F
authors.lastname: Rozet
authors.forename: G
authors.initials: G
authors.lastname: Fromont
authors.forename: C
authors.initials: C
authors.lastname: Hennequin
authors.forename: R
authors.initials: R
authors.lastname: Renard-Penna
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.forename: P
authors.initials: P
authors.lastname: Richaud
authors.forename: M
authors.initials: M
authors.lastname: Soulié
authors.forename: L
authors.initials: L
authors.lastname: Salomon
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000517:prevention & control*
chemical_list: D058891:5-alpha Reductase Inhibitors